Lunitは、AIを通じてがんに打ち勝つことを目指す医療AI企業です。がんの診断と治療のためのAI駆動ソリューションを提供し、臨床医が早期がんをより正確に検出し、治療への患者の反応を予測するのを支援します。その製品は医療画像と組織データを分析し、臨床成果を向上させます。
製品概要
Lunit 製品概要
Lunitは、AIを通じてがんに打ち勝つことを目指す医療AI企業です。がんの診断と治療のためのAI駆動ソリューションを提供し、臨床医が早期がんをより正確に検出し、治療への患者の反応を予測するのを支援します。その製品は医療画像と組織データを分析し、臨床成果を向上させます。
Rayscape 製品概要
医療専門家が胸部X線(CXR)および肺CTスキャンを分析するのを支援するために設計されたAI搭載の放射線科プラットフォームです。最大148の病状(肺結節や結核を含む)を自動的に検出し、既存の臨床ワークフローにシームレスに統合することで、診断の精度と効率を向上させます。
Detailed feature comparison
| Feature | Lunit | Rayscape |
|---|---|---|
| 主要カテゴリー | 予測分析 | 診断 |
| 追加日 | 2025-08-02 | 2025-08-07 |
| 価格 | 未確認 | 未確認 |
| 公式サイト | www.lunit.io | rayscape.ai |
| 製品タイプ | ウェブサイト | ウェブサイト |
| Performance data | ||
| ユーザー評価 | 未確認 | 未確認 |
| コメント | 0 | 0 |
| 月間訪問数 | 38.4K | 6.5K |
| 月間成長率 | -7.6% | -14.3% |
| お気に入り | 85 | 99 |
| Details | 詳細を見る | 詳細を見る |
Lunit vs Rayscape monthly traffic
Compare Lunit and Rayscape by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
How to interpret the traffic data
In the Lunit vs Rayscape monthly traffic comparison, Lunit currently shows 38.4K visits and Rayscape shows 6.5K; Lunit has about 5.9 times the visible traffic of Rayscape, an absolute difference of about 31.8K visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
Lunit is registered at the www.lunit.io/en subpage. Because the current data does not state whether other host pages are excluded, treat this as domain-level context rather than independent traffic for one product or project.
Lunit monthly traffic:
Latest traffic
Monthly traffic trend
- 2026/1: 35.8K 月間訪問数
- 2026/2: 35.2K 月間訪問数
- 2026/3: 41.4K 月間訪問数
- 2026/4: 41.5K 月間訪問数
- 2026/5: 38.4K 月間訪問数
主要地域
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 36.04% | 13.8K |
| 🇰🇷Korea, Republic of | 25.34% | 9.7K |
| 🇮🇳India | 16.94% | 6.5K |
| 🇻🇳Vietnam | 14.38% | 5.5K |
| 🇹🇷Turkey | 7.3% | 2.8K |
流入元
| Source type | Percentage | Traffic |
|---|---|---|
| ダイレクト | 92.51% | 35.5K |
| 参照元 | 5.74% | 2.2K |
| Eメール | 1.75% | 671 |
検索キーワード
Rayscape monthly traffic:
Latest traffic
Monthly traffic trend
- 2025/9: 4K 月間訪問数
- 2026/1: 4.4K 月間訪問数
- 2026/2: 3.5K 月間訪問数
- 2026/3: 1.5K 月間訪問数
- 2026/4: 7.6K 月間訪問数
- 2026/5: 6.5K 月間訪問数
主要地域
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 39.64% | 2.6K |
| 🇹🇷Turkey | 30.2% | 2K |
| 🇮🇳India | 30.16% | 2K |
検索キーワード
Usage comparison
Compare the core capabilities of Lunit and Rayscape
Lunit Core features
Rayscape Core features
Use cases
Lunit Use cases
Rayscape Use cases
Lunit vs Rayscape:In-depth comparison and selection guidance
First decide whether the products solve the same kind of need
This in-depth Lunit vs Rayscape comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. Lunit is primarily listed under “予測分析”, while Rayscape is primarily listed under “診断”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Primary category (Lunit: 予測分析; Rayscape: 診断); Monthly visits (Lunit: 38.4K; Rayscape: 6.5K); Monthly growth (Lunit: -7.6%; Rayscape: -14.3%); Favorites (Lunit: 85; Rayscape: 99); Website (Lunit: www.lunit.io; Rayscape: rayscape.ai). These facts are more useful for selection than brand visibility alone.
What market visibility and monthly traffic mean
In the Lunit vs Rayscape monthly traffic comparison, Lunit currently shows 38.4K visits and Rayscape shows 6.5K; Lunit has about 5.9 times the visible traffic of Rayscape, an absolute difference of about 31.8K visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
Lunit is registered at the www.lunit.io/en subpage. Because the current data does not state whether other host pages are excluded, treat this as domain-level context rather than independent traffic for one product or project.
Lunit is registered under a www.lunit.io subpath, so its large visible total may include the host platform. The current data does not justify choosing Lunit for traffic alone; shortlist by unique taxonomy and use case, then validate with the same tasks.
Product positioning, use cases, and roles
Lunit and Rayscape currently overlap in shared categories: 医用画像; shared tags: AI診断、医療AI、医用画像、放射線医学. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
Lunit's unique categories/tags are 予測分析、腫瘍学、バイオマーカー、癌検出、ディープラーニング、免疫療法; Rayscape's are 診断、データ分析、胸部X線、臨床意思決定支援、肺CT、肺結節検出、結核検出. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
What ratings, comments, and favorites can tell you
Lunit has no verified rating, 0 comments, 85 favorites, and 87 likes;Rayscape has no verified rating, 0 comments, 99 favorites, and 92 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Selection guidance by actual need
When to evaluate Lunit first
Put Lunit on the priority trial list when the task aligns with “予測分析” and especially 予測分析、腫瘍学、バイオマーカー、癌検出、ディープラーニング、免疫療法. This follows recorded positioning and does not imply unlisted capabilities are absent.
Lunit also currently records: pricing is not verified, product type is website, 38.4K monthly visits shown for the registered host (subpage scope unknown), no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
When to evaluate Rayscape first
Put Rayscape on the priority trial list when the task aligns with “診断” and especially 診断、データ分析、胸部X線、臨床意思決定支援、肺CT、肺結節検出. This follows recorded positioning and does not imply unlisted capabilities are absent.
Rayscape also currently records: pricing is not verified, product type is website, 6.5K verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
How to validate the recommendation before deciding
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in Lunit and Rayscape, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.




